Researchers have responded to recent commentary about anti-MRSA treatment options for community-acquired pneumonia, reaffirming their position on selective therapeutic approaches. The correspondence, published in The Lancet, addresses concerns raised by Alberto Enrico Maraolo and colleagues regarding the expanding range of treatments available for meticillin-resistant Staphylococcus aureus infections.